凯普生物
(300639)
| 流通市值：32.58亿 | | | 总市值：33.17亿 |
| 流通股本：6.35亿 | | | 总股本：6.47亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 125,833,690.97 | 669,642,058.53 | 485,871,698.54 | 314,993,117.77 |
| 营业收入 | 125,833,690.97 | 669,642,058.53 | 485,871,698.54 | 314,993,117.77 |
| 二、营业总成本 | 151,542,295.24 | 774,736,219.2 | 576,383,507.2 | 375,396,099.82 |
| 营业成本 | 70,897,083.27 | 365,187,752.55 | 254,789,601.57 | 167,001,818.14 |
| 税金及附加 | 2,631,838.87 | 11,748,919.42 | 6,892,943.82 | 4,236,014.19 |
| 销售费用 | 35,754,179.54 | 166,884,445.33 | 138,029,939.68 | 90,742,288.05 |
| 管理费用 | 50,604,283.18 | 206,497,211.78 | 153,047,290.08 | 101,183,145 |
| 研发费用 | 13,315,753.31 | 62,385,576.27 | 48,250,149.62 | 34,052,944.72 |
| 财务费用 | -21,660,842.93 | -37,967,686.15 | -24,626,417.57 | -21,820,110.28 |
| 其中:利息费用 | 814,694.37 | 3,183,250.62 | 2,843,503.55 | 1,059,827.46 |
| 其中:利息收入 | 3,509,206.38 | 18,411,066.3 | 14,078,088.26 | 10,290,871.93 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,428.63 | 4,973,032.53 | 3,214,052.48 | 4,438,941.3 |
| 加:投资收益 | -23,555.82 | -1,125,109.6 | 986,803.06 | 243,383.24 |
| 资产处置收益 | -315,660.22 | 434,231.78 | 589,434.13 | 358,182.51 |
| 资产减值损失(新) | -52,664.16 | -27,334,497.51 | -10,437,663.57 | -10,894,159.27 |
| 信用减值损失(新) | 21,286,742.74 | -34,934,898.12 | -79,333,119.27 | -57,564,018.85 |
| 其他收益 | 1,360,075.52 | 6,675,766.57 | 4,657,890.82 | 2,143,073.8 |
| 四、营业利润 | -3,450,237.58 | -156,405,635.02 | -170,834,411.01 | -121,677,579.32 |
| 加:营业外收入 | 19,354.6 | 2,186,321.99 | 563,533.65 | 90,302.4 |
| 减:营业外支出 | 237,482.04 | 15,101,546.99 | 7,088,698.05 | 5,574,138.07 |
| 五、利润总额 | -3,668,365.02 | -169,320,860.02 | -177,359,575.41 | -127,161,414.99 |
| 减:所得税费用 | 2,759,824.74 | 12,959,540.23 | 12,018,946.17 | 9,955,385.37 |
| 六、净利润 | -6,428,189.76 | -182,280,400.25 | -189,378,521.58 | -137,116,800.36 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -6,428,189.76 | -182,280,400.25 | -189,378,521.58 | -137,116,800.36 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -2,796,512.44 | -130,942,453.04 | -127,683,325.23 | -89,591,424.25 |
| 少数股东损益 | -3,631,677.32 | -51,337,947.21 | -61,695,196.35 | -47,525,376.11 |
| 扣除非经常损益后的净利润 | -9,800,385.3 | -170,960,198.41 | -135,389,739.28 | -95,610,389.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | -0.21 | -0.2 | -0.14 |
| (二)稀释每股收益 | 0 | -0.21 | -0.2 | -0.14 |
| 八、其他综合收益 | 74,742,906.91 | -66,747,487.14 | -37,137,367.19 | -21,365,718.72 |
| 归属于母公司股东的其他综合收益 | 74,742,906.91 | -66,747,487.14 | -37,137,367.19 | -21,365,718.72 |
| 九、综合收益总额 | 68,314,717.15 | -249,027,887.39 | -226,515,888.77 | -158,482,519.08 |
| 归属于母公司股东的综合收益总额 | 71,946,394.47 | -197,689,940.18 | -164,820,692.42 | -110,957,142.97 |
| 归属于少数股东的综合收益总额 | -3,631,677.32 | -51,337,947.21 | -61,695,196.35 | -47,525,376.11 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-29 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |